智通财经6月10日电，截至发稿，博安生物(06955.HK)涨8.96%、宜明昂科-B(01541.HK)涨7.67%、泰格 医药(03347.HK)涨5.32%、昭衍新药(06127.HK)涨5.41%。 港股医药股延续涨势 博安生物涨近9% ...

格隆汇6月4日丨博安生物(06955.HK)发布公告，2025年6月3日，公司及配售代理(即瑞银集团)订立配售 协议，据此，公司同意委任配售代理，而配售代理同意作为公司的代理促使买方按配售价竭诚购买配售 股份，惟须遵守配售协议所载条款及受当中所载条件规限。 假设总计3840万股配售股份将获出售，配售事项所得款项总额预期将约为4亿港元。预期配售事项所得 款项净额约为3.96亿港元。公司拟将配售事项的所得款项净额用作以下用途：(a)约50%将用于创新候选 产品的研发，包括：(i)BA1106(CD25抗体)、BA1301 (Claudin18.2 ADC)及BA1302 (CD228 ADC)的临床 试验；(ii)BA1304(EGFR/B7H3双特异性ADC)及PR201(PD-1/IL-2掩蔽抗体)的非临床研究及临床试验； 及(iii)其他具有市场潜力的创新候选产品的概念验证；(b)约20%将用于已上市及即将上市产品的商业 化；及(c)约30%将用于补充公司营运资金及一般企业用途。 可能根据配售事项出售的配售股份总数为3840万股，相当于本公告日期的已发行股份总数约7.17%；及 经配发及发行配售股份扩大的已 ...

5月30日，截至港股收盘，恒生指数下跌1.2%，报23289.77点。博安生物（06955.HK）收报11.82港元/ 股，上涨18.2%，成交量6783.66万股，成交额7.77亿港元，振幅23.1%。 最近一个月来，博安生物累计跌幅7.24%，今年来累计涨幅7.18%，跑输恒生指数17.51%的涨幅。 博安生物拥有完整的涵盖抗体发现、细胞株开发、上游及下游工艺开发、分析及生物分析方法开发、技 术转移、非临床研究、临床研究、法规与注册及商业化规模生产的全整合型产业链。在细胞治疗领域, 博安聚焦新—代增虽型及可调控T细胞治疗技术,研发更安全、有效、可负担的细胞治疗产品。 目前,博安生物已拥有三款商业化产品,以及多个具有国际知识产权保护的创新型生物药和生物类似药的 在研产品组合。公司荣获"国家高新技术企业"认定,并拥有"山东省省级新型研发机构"及"山东省工程研 究中心"等省级技术平台。除了在中国,博安生物也在包括欧美地区在内的海外市场从事生物药产品开 发。基于差异化的产品组合,以及不断成熟的商业化能力,博安生物已构建起覆盖"研发-生产-商业化"的 全产业价值链运营体系,为其长期的高质量发展奠定坚实基础。 （以上 ...

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue reached approximately RMB 726.3 million, an increase of about RMB 108.2 million or 17.5% compared to RMB 618.1 million for the previous year[9]. - The company's gross profit for the same period was approximately RMB 542.6 million, reflecting an increase of about RMB 133.7 million or 32.7% year-over-year[11]. - The company recorded a net profit of RMB 73.2 million for the fiscal year, a significant improvement from a net loss of RMB 119.4 million in the previous year[14]. - The company achieved a revenue of RMB 726.3 million for the year ended December 31, 2024, representing a year-on-year growth of 17.5%[21]. - Gross profit reached RMB 542.6 million, with a significant increase of 32.7% year-on-year, resulting in a gross margin of 74.7%, up by 8.5 percentage points[21]. - Net profit surged to RMB 73.2 million, marking a substantial increase of RMB 192.6 million year-on-year[21]. - Other income and gains amounted to approximately RMB 45.1 million for the year ending December 31, 2024, compared to RMB 27.7 million in 2023, primarily due to government subsidies[69]. - The company's financing costs increased by approximately RMB 18.6 million or 131.9% to RMB 32.7 million for the year ending December 31, 2024, due to interest expenses from loans and financing leases[74]. - The company recorded a profit of RMB 73.2 million for the year ending December 31, 2024, compared to a loss of RMB 119.4 million for the year ending December 31, 2023[76]. Research and Development - Research and development expenses for the year were approximately RMB 149.3 million, a decrease of about RMB 81.4 million compared to RMB 230.7 million in the previous year[13]. - The company has developed a comprehensive value chain covering R&D, production, and commercialization, ensuring long-term high-quality growth[20]. - The company is focused on innovative biopharmaceuticals, with several products in various stages of clinical development, including ADCs and T-cell therapies[20]. - The company has a robust R&D platform with teams in Yantai, Nanjing, and Boston, focusing on antibody discovery and drug development[45]. - The R&D team consists of 286 experienced employees, most with over seven years of experience in drug development and clinical research[46]. - The proprietary technology platforms include fully human antibody transgenic mice and bispecific T-cell engager technology, enhancing the company's competitive edge[45]. Product Development and Pipeline - The company has three commercialized products and is developing multiple innovative biopharmaceuticals with international intellectual property protection[6]. - The product pipeline includes three commercialized products, two candidates under review for biopharmaceutical licensing, and six candidates in clinical trials, focusing on oncology, metabolism, autoimmune, and ophthalmology[27]. - Two candidate drugs have entered the BLA stage in China, with BA5101 being the only submitted biosimilar of its kind globally[22]. - The company expects multiple new products to be approved for market entry in China and overseas between 2025 and 2027, including BA5101 and BA9101[17]. - BA1104 is currently in Phase III clinical trials in China, with a simplified clinical strategy approved by the FDA for BLA submission[17]. - BA1101 (Bevacizumab Injection) has been approved for six indications, including metastatic colorectal cancer and advanced non-small cell lung cancer, and is included in China's national medical insurance catalog[29]. - BA6101 (Densumab Injection) has been approved for the treatment of postmenopausal women with osteoporosis at high risk of fracture and is also included in China's national medical insurance catalog[29]. - BA1102 (Densumab Injection) is expected to be approved in China by May 2024 for treating unresectable giant cell tumors of bone, with ongoing efforts for its use in solid tumor bone metastases[29]. - BA5101 (Dulaglutide Injection) is the first biosimilar developed by a Chinese company approved for clinical trials in the US for type 2 diabetes management[30]. - BA9101 (Aflibercept Injection) is in collaboration with EOC Pharma for commercialization in China, with its application for drug approval accepted by the National Medical Products Administration in May 2024[31]. Market Expansion and Partnerships - The company is expanding its market presence in the United States, European Union, and Japan, in addition to its operations in China[6]. - The company is actively exploring international commercialization partnerships for products already launched or in clinical trials in China[25]. - The company is collaborating with various well-resourced business partners to enhance its market presence and accelerate the commercialization of its products[53]. - The company has established partnerships and joint ventures, such as with Peking University, to enhance its research and development capabilities in modern Chinese medicine[105]. Financial Position and Capital Management - The total assets of the company increased to RMB 2,851.3 million, while total liabilities rose to RMB 1,207.3 million, indicating a solid financial foundation for future growth[14]. - Cash and cash equivalents as of December 31, 2024, were RMB 198.9 million, a decrease of 1.49% from RMB 201.9 million as of December 31, 2023[77]. - The current ratio improved from approximately 1.09 as of December 31, 2023, to approximately 1.47 as of December 31, 2024, indicating better liquidity[77]. - As of December 31, 2024, the company's interest-bearing bank loans and other borrowings totaled approximately RMB 678.9 million, an increase of RMB 282.7 million from RMB 396.2 million as of December 31, 2023[78]. - The company's debt-to-equity ratio increased from 30.0% as of December 31, 2023, to 41.3% as of December 31, 2024, primarily due to the increase in bank loans and other borrowings during the reporting period[79]. - The company's capital expenditures for the year ended December 31, 2024, were RMB 45.8 million, down from RMB 104.3 million in 2023[81]. Corporate Governance - The company is committed to maintaining high standards of corporate governance, as evidenced by the qualifications and experience of its independent directors[107][108]. - The board consists of seven members, including two executive directors, two non-executive directors, and three independent non-executive directors as of December 31, 2024[196]. - The company has established a remuneration committee to review the compensation policy and structure for directors and senior management[155]. - The independent directors are expected to contribute to the company's strategic direction and market expansion efforts[109]. - The board has established five committees: Audit Committee, Remuneration Committee, Nomination Committee, Strategic Committee, and Environmental, Social, and Governance Committee[196]. Risk Management - The company has faced various risks that could impact its financial condition and operational performance, including market, operational, investment, human resources, and financial risks[127][128][129][130][132]. - The management is responsible for monitoring and managing market risks to ensure timely and effective measures are taken[128]. - The company has established risk management procedures to minimize significant risks that could potentially impact its business objectives[132]. Employee and Social Responsibility - The company has maintained good relationships with employees, customers, and suppliers, ensuring fair evaluations and complaint handling mechanisms[135][136]. - The group has established a compensation policy aimed at incentivizing and retaining talented employees to achieve long-term corporate goals[155]. - The company is committed to environmental sustainability and has implemented various green office measures[133].

4月17日，截至港股收盘，恒生指数上涨1.61%，报21395.14点。博安生物（06955.HK）收报13.76港元/ 股，上涨66.99%，成交量3049.86万股，成交额4.48亿港元，振幅203.4%。 最近一个月来，博安生物累计跌幅6.26%，今年来累计跌幅11.68%，跑输恒生指数4.97%的涨幅。 财务数据显示，截至2024年12月31日，博安生物实现营业总收入7.26亿元，同比增长17.5%；归母净利 润7318.9万元，同比增长161.31%；毛利率74.71%，资产负债率42.34%。 机构评级方面，华安证券股份有限公司给予"买入"评级。 行业估值方面，药品及生物科技行业市盈率（TTM）平均值为5.89倍，行业中值4.7倍。博安生物市盈 率55.88倍，行业排名第70位；其他精优药业（00858.HK）为0.63倍、金斯瑞生物科技（01548.HK）为 0.98倍、百信国际（00574.HK）为1.49倍、东瑞制药（02348.HK）为2.78倍、帝王国际投资 （00928.HK）为4.43倍。 资料显示，山东博安生物技术股份有限公司(6955.HK)是—家全面综合性生物制药公司,专业从事 ...

港股博安生物冲高后回落，涨幅收窄至110%。 ...

港股博安生物(06955.HK)尾盘冲高后快速回落，现涨88%。 ...

港股博安生物(06955.HK)尾盘持续拉升，最高涨超200%。 ...

智通财经4月17日电，港股博安生物持续拉升，涨幅扩大至200%，成交超2亿港元。 ...

港股博安生物尾盘走强，盘中涨超50%。 无需港股通，A股账户就能T+0买港股>> ...